<DOC>
	<DOCNO>NCT02903576</DOCNO>
	<brief_summary>This study Phase I/II , open label , non randomize , prospective study determine safety human embryonic stem cell derive Retinal pigment epithelium ( hESC RPE ) sub retinal injection versus hESC RPE seed polymeric substrate implant sub retinal space ,</brief_summary>
	<brief_title>Stem Cell Therapy Outer Retinal Degenerations</brief_title>
	<detailed_description>To determine whether surgical implantation human embryonic stem cell-derived retinal pigment epithelium ( hESC-RPE ) monolayer seed onto polymeric versus hESC-RPE injection sub retinal space safe procedure . 6 Patients receive hESC-RPE cell injection ( 100000 cell ) sub retinal space ( 2 Dry Age-related macular degeneration ( AMD ) , 2 Wet AMD disciform scar 2 Stargardt 's disease ) . Also 5 patient Dry AMD , 5 patient Wet AMD disciform scar 5 patient Stargardt 's disease receive subretinal implantation hESC-RPE seed monolayer polymeric substrate . Patients enrol sequentially , procedure patient follow 1 year .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<criteria>Patients AMD ( Dry , Wet failure treatment , disciform scar ) Patients Stargardt 's Disease BCVA select eye : bad 20/200 Other ophthalmological disease ( Glaucoma , Diabetic Retinopathy , Previous retinal surgery , uveitis ) Systemic diseases contraindication surgical procedure local anaesthesia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>